As described in Section 3, CXCL9 production by cDC1s is negatively regulated by TIM-3 on their cell surface, and clinical trials are currently being conducted for several anti-TIM-3 monoclonal antibodies such as cobolimab, MBG453, LY3321367, and BMS986258, aiming at the upregulation of CXCL9 expression in the tumor microenvironment [217]. This evidence concerns the gene HAVCR2 and neoplasm.